National Heart, Lung, And Blood Institute (nhlbi)
Clinical trials sponsored by National Heart, Lung, And Blood Institute (nhlbi), explained in plain language.
-
New drug aimed at stopping lung rejection in transplant patients
Disease control Not yet recruitingThis early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with the…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New scan could spot hidden scarring in heart and lungs before It's too late
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…
Phase: PHASE3 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Diagnosis
Last updated Jul 02, 2026 01:00 UTC
-
Super-Resolution heart scans: sharper images without extra radiation?
Knowledge-focused Not yet recruitingThis study will take standard heart CT scans from 1000 adults with structural heart disease and use a super-computer to create ultra-high-resolution images. The goal is to see if these enhanced images show more detail than the originals. No new treatments are being tested; it's a…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 01:00 UTC